Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months
| Autor: | Linda L. Yasukawa, Ross DeHovitz, Susette Audet, Hayley A. Gans, Judith Beeler, Ann M. Arvin, Mary Rinki, Bagher Forghani, Yvonne Maldonado |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
T-Lymphocytes Measles Vaccine Mumps Vaccine Mumps virus medicine.disease_cause Antibodies Viral Measles Measles virus Cohort Studies Interferon-gamma Immunology and Allergy Medicine Humans Seroconversion Mumps biology business.industry Vaccination Age Factors Infant biology.organism_classification medicine.disease Virology Infectious Diseases Rubulavirus Immunization Morbillivirus Mumps vaccine Immunology Measles vaccine business Measles-Mumps-Rubella Vaccine |
| Zdroj: | The Journal of infectious diseases. 184(7) |
| ISSN: | 0022-1899 |
| Popis: | Immunizing infants against measles at the youngest age possible has the potential to reduce morbidity and mortality. The ability of infants at 6, 9, or 12 months to respond to measles and mumps vaccines was evaluated by measuring T cell proliferation, interferon-gamma production, and neutralizing antibody titers before and after vaccination. Infants in all age groups had equivalent cellular immune responses to measles or mumps viruses, with or without passive antibodies when immunized. In contrast, 6-month-old infants without passive antibodies had low geometric mean titers of antibody to measles or mumps viruses and low seroconversion rates. Geometric mean titers of antibody to measles virus increased if infants were revaccinated at 12 months. Six-month-old infants had limited humoral responses to paramyxovirus vaccines, whereas cellular immunity was equivalent to that of older infants. T cell responses can be established by immunization with these live attenuated virus vaccines during the first year, despite the presence of passive antibodies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|